Norges Bank Bridge Bio Pharma, Inc. Transaction History

Norges Bank

$716 Trillion
Q3 2024

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$23.0 - $31.04 $20.6 Million - $27.7 Million	893,729 New	893,729 $22.6 Million
Q4 2023 Feb 09, 2024	BUY	$24.02 - $43.89 $27.9 Million - $50.9 Million	1,160,342 New	1,160,342 $46.8 Million
Q3 2023 Nov 13, 2024	BUY	$16.89 - $35.01 $8.38 Million - $17.4 Million	496,088 New	496,088 $13.1 Million
Q3 2023 Nov 13, 2023	SELL	$16.89 - $35.01 $16.2 Million - $33.6 Million	-960,595 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$13.29 - $18.01 $1.75 Million - $2.37 Million	-131,423 Reduced 14.71%	762,306 $13.1 Million
Q2 2023 Aug 14, 2023	SELL	$13.29 - $18.01 $12.8 Million - $17.3 Million	-960,595 Closed	0 $0
Q1 2023 May 15, 2024	BUY	$7.17 - $18.55 $5.47 Million - $14.1 Million	762,306 New	762,306 $12.6 Million
Q4 2022 Feb 14, 2023	BUY	$6.74 - $11.52 $6.47 Million - $11.1 Million	960,595 New	960,595 $7.32 Million
Q3 2022 Nov 13, 2023	BUY	$7.94 - $12.36 $7.63 Million - $11.9 Million	960,595 New	960,595 $9.55 Million
Q2 2022 Aug 14, 2023	BUY	$5.21 - $12.14 $5 Million - $11.7 Million	960,595 New	960,595 $8.72 Million
Q1 2022 May 12, 2023	BUY	$7.34 - $17.16 $978,422 - $2.29 Million	133,300 Added 13.88%	1,093,895 $11.1 Million
Q1 2022 May 09, 2022	SELL	$7.34 - $17.16 $6.62 Million - $15.5 Million	-901,495 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$11.38 - $53.41 $10.3 Million - $48.1 Million	901,495 New	901,495 $15 Million
Q3 2021 Nov 14, 2022	BUY	$46.87 - $64.24 $39.1 Million - $53.5 Million	833,232 New	833,232 $39.1 Million
Q3 2021 Nov 05, 2021	SELL	$46.87 - $64.24 $38.6 Million - $53 Million	-824,432 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$46.47 - $63.93 $38.3 Million - $52.7 Million	824,432 New	824,432 $50.3 Million
Q2 2021 Aug 10, 2021	SELL	$46.47 - $63.93 $33.9 Million - $46.6 Million	-728,829 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$55.47 - $72.35 $40.4 Million - $52.7 Million	728,829 New	728,829 $44.9 Million
Q1 2021 May 07, 2021	SELL	$55.47 - $72.35 $35.1 Million - $45.8 Million	-632,984 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$38.38 - $71.11 $24.3 Million - $45 Million	632,984 New	632,984 $45 Million
Q4 2020 Feb 10, 2021	SELL	$38.38 - $71.11 $22 Million - $40.8 Million	-573,063 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$27.2 - $42.19 $15.6 Million - $24.2 Million	573,063 New	573,063 $21.5 Million
Q3 2020 Nov 10, 2020	SELL	$27.2 - $42.19 $3.31 Million - $5.14 Million	-121,817 Closed	0 $0
Q2 2020 Aug 13, 2021	BUY	$22.22 - $35.69 $2.71 Million - $4.35 Million	121,817 New	121,817 $3.97 Million
Q2 2020 Aug 07, 2020	SELL	$22.22 - $35.69 $2.71 Million - $4.35 Million	-121,817 Closed	0 $0
Q1 2020 May 07, 2021	BUY	$16.11 - $36.23 $1.96 Million - $4.41 Million	121,817 New	121,817 $3.53 Million
Q1 2020 May 08, 2020	SELL	$16.11 - $36.23 $1.96 Million - $4.41 Million	-121,817 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$17.96 - $46.63 $2.19 Million - $5.68 Million	121,817 New	121,817 $4.27 Million
Q4 2019 Feb 12, 2020	SELL	$17.96 - $46.63 $2.69 Million - $6.99 Million	-150,000 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$20.13 - $32.38 $3.02 Million - $4.86 Million	150,000 New	150,000 $3.22 Million
Q3 2019 Nov 08, 2019	SELL	$20.13 - $32.38 $6.04 Million - $9.71 Million	-300,000 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$26.97 - $27.55 $8.09 Million - $8.27 Million	300,000 New	300,000 $8.09 Million

Others Institutions Holding BBIO

# of Institutions

294

Shares Held

171M

Call Options Held

10.4M

Put Options Held

2.36M

Kohlberg Kravis Roberts & Co. L.P. New York, NY

25.3M
Shares

$864 Million
35.94% of portfolio
Viking Global Investors LP

25.1M
Shares

$859 Million
2.47% of portfolio
Vanguard Group Inc Valley Forge, PA

14.2M
Shares

$486 Million
0.01% of portfolio
Black Rock Inc. New York, NY

12.4M
Shares

$426 Million
0.01% of portfolio
Aisling Capital Management LP New York, NY

6.07M
Shares

$208 Million
63.58% of portfolio

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $5.07B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account